A Bayesian phase I/II trial design for immunotherapy
DOI10.1080/01621459.2017.1383260zbMATH Open1402.62278OpenAlexW2758838926WikidataQ91332747 ScholiaQ91332747MaRDI QIDQ4559685FDOQ4559685
Authors: Suyu Liu, Beibei Guo, Ying Yuan 
Publication date: 4 December 2018
Published in: Journal of the American Statistical Association (Search for Journal in Brave)
Full work available at URL: http://europepmc.org/articles/pmc6860919
Recommendations
- A Bayesian adaptive design for addressing correlated late-onset outcomes in phase I/II randomized trials of drug combinations in oncology
- A batch‐effect adjusted Simon's two‐stage design for cancer vaccine clinical studies
- Adaptive clinical trial designs for phase I cancer studies
- scientific article; zbMATH DE number 2242805
- A Parallel Phase I/II Clinical Trial Design for Combination Therapies
immune responseimmunotherapydose findingphase I/II trialBayesian adaptive designrisk-benefit tradeoff
Applications of statistics to biology and medical sciences; meta analysis (62P10) Bayesian problems; characterization of Bayes procedures (62C10)
Cites Work
- Title not available (Why is that?)
- Dose-Finding Based on Efficacy-Toxicity Trade-Offs
- Bayesian Dose-Finding in Phase I/II Clinical Trials Using Toxicity and Efficacy Odds Ratios
- Bayesian phase I/II adaptively randomized oncology trials with combined drugs
- Utility-Based Optimization of Combination Therapy Using Ordinal Toxicity and Efficacy in Phase I/II Trials
- Using joint utilities of the times to response and toxicity to adaptively optimize schedule-dose regimes
- Bayesian designs for phase I--II clinical trials
Cited In (9)
- A Bayesian adaptive design for dual-agent phase I-II oncology trials integrating efficacy data across stages
- Biomarker-based precision dose finding for immunotherapy combined with radiotherapy
- BIPSE: a biomarker-based phase I/II design for immunotherapy trials with progression-free survival endpoint
- DROID: dose-ranging approach to optimizing dose in oncology drug development
- A Bayesian design for phase I cancer therapeutic vaccine trials
- REDOMA: Bayesian random-effects dose-optimization meta-analysis using spike-and-slab priors
- A Bayesian phase I/II platform design for co-developing drug combination therapies for multiple indications
- Hybrid design evaluating new biomarkers when there is an existing screening test
- A Bayesian adaptive phase i/II platform trial design for pediatric immunotherapy trials
This page was built for publication: A Bayesian phase I/II trial design for immunotherapy
Report a bug (only for logged in users!)Click here to report a bug for this page (MaRDI item Q4559685)
